· Published by Health Canada · Official notice
December 21, 2012
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Cardiac Surgery, Cardiology, Neurology, Hematology, Pharmacy, Paediatrics, Geriatrics, Internal Medicine, Nursing, Intensive Care and/or other Departments as required, and other involved professional staff and post this notice in your institution.
Subject: Pradaxa/Pradax (dabigatran etexilate): New contraindication in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status
Health Canada would like to inform you about important new safety information relating to the use of Pradaxa (dabigatran etexilate), also known as Pradax, in patients with prosthetic heart valves. Based on recent information, the Pradaxa Product Monograph (PM) will be revised to include a new contraindication for use in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status.
This change is based on interim results from a phase II trial (RE-ALIGNFootnote 1) which compared dabigatran etexilate and warfarin in a total of 252 patients with prosthetic heart valves. The study investigated a dose range of 150 mg twice daily to 300 mg twice daily in patients with recent mechanical heart valve replacement surgery (within the associated hospital stay) and in patients who received mechanical heart valve replacement more than three months before. More thromboembolic events and more bleeding events were observed with dabigatran etexilate than with warfarin, especially in patients who were randomised post-surgery, i.e., soon after mechanical valve placement. Boehringer Ingelheim has decided to discontinue the study and update the worldwide labelling to contraindicate the use of Pradaxa in patients with prosthetic heart valves.
Pradaxa should not be used to prevent valve thrombosis or thromboembolism (e.g., stroke, myocardial infarction, systemic embolism, prosthetic mechanical valve thrombosis, and vascular death) in patients with prosthetic heart valves. The European RE-ALIGN trial was terminated early because thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) were significantly more frequent in the Pradaxa treatment arm than in the warfarin treatment arm. The use of Pradaxa has not been evaluated in patients with bioprosthetic valves or other forms of valvular heart disease.
As of December 10, 2012, the following RE-ALIGN trial interim data has been provided by the manufacturer:
| Pradaxa (n=160)* | Warfarin (n=89)* | |
|---|---|---|
| Death | 1 (0.6%) | 2 (2.2%) |
| Stroke | 8 (5.0%) | 0 |
| Systemic embolism event (SEE) | 0 | 0 |
| Transient ischemic attack (TIA) | 2 (1.3%) | 2 (2.2%) |
| Valve thrombosis (VT) | 4 (2.5%) | 0 |
| Myocardial infarction (MI) | 3 (1.9%) | 0 |
|
Composite of events: Death/stroke/SEE/TIA/VT/MI |
16 (10.0%) | 4 (4.5%) |
| Major bleeding | 6 (3.8%) | 1 (1.1%) |
| Major bleeding in pericardial location | 5 (3.1%) | 0 |
| Any bleeding | 36 (22.5%) | 12 (13.5%) |
* Because of dose up−titrations on dabigatran and switches from dabigatran to warfarin, patients can contribute events to both columns.
Pradaxa (dabigatran etexilate) is an oral anticoagulant authorized for sale in Canada for the prevention of venous thromboembolic events in patients following hip or knee replacement surgery and for the prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate.Footnote 3 Pradaxa is currently not recommended for use in patients with prosthetic heart valves, with or without atrial fibrillation, see WARNINGS AND PRECAUTIONS, Cardiovascular, Patients with Valvular Disease of the current Product Monograph.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious thromboembolic or cardiovascular adverse reactions or other serious or unexpected adverse reactions in patients receiving Pradaxa should be reported to Boehringer-Ingelheim (Canada) Ltd or Health Canada.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffectTM Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
References:
Van de Werf, F, Brueckman M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012; 163:931-937.e1.
FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. Accessed December 21, 2012.
PradaxaTM Product Monograph, dated November 28, 2012
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738